B&K (HKSE:02396) General and Admin. Expense: HK$120.71 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$4.40
! 1 Warning Sign
View Full Analysis

What is B&K General and Admin. Expense?

B&K HKSE:02396 8 General and Admin. Expense is HK$120.71 Mil as of Dec. 2025. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. B&K's General and Admin. Expense for the three months ended in Dec. 2025 was HK$120.71 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$120.71 Mil.

B&K General and Admin. Expense Related Terms

B&K General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for B&K's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K General and Admin. Expense Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
General and Admin. Expense
16.62 124.68 130.98

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
General and Admin. Expense 0.00 111.72 0.00 0.00 120.71
HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$120.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of HK$120.71 Mil mean?
B&K (HKSE:02396) has a General and Admin. Expense of HK$120.71 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on B&K and its competitors.
Is B&K's General and Admin. Expense too high?
B&K's current General and Admin. Expense is HK$120.71 Mil. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's General and Admin. Expense compare to VRTX and REGN?
B&K's General and Admin. Expense of HK$120.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on B&K and its competitors. B&K's current General and Admin. Expense is HK$120.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current General and Admin. Expense of HK$120.71 Mil. The current General and Admin. Expense is HK$120.71 Mil. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For B&K (HKSE:02396), the current General and Admin. Expense is HK$120.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.40
Price